Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema

William Lumry, Daniel Soteres, Richard Gower, Kraig W. Jacobson, Huamin Li, Hongzi Chen, Jennifer Schranz

Research output: Contribution to journalArticle

Abstract

Background: Human plasma-derived nanofiltered C1 esterase inhibitor (C1 INH-nf) is used to treat acute angioedema attacks in patients with hereditary angioedema (HAE), but data regarding use in children are sparse. Methods: Patients 2 to 25 kg). Each weight category included 2 dosing levels: C1 INH-nf (500 units [U], 1000 U) and C1 INH-nf (1000 U, 1500 U), respectively. Patients experiencing an angioedema attack were given a single intravenous dose. Primary efficacy end-point was the onset of unequivocal relief of the defining symptom within 4 h following initiation of C1 INH-nf treatment. Results: Nine children were treated: 3 (10-25 kg) received 500 U; 3 (>25 kg) received 1000 U; and 3 (>25 kg) received 1500 U. The lower weight/higher dose category (10-25 kg, 1000 U) was not successfully enrolled. All patients completed the study. Most angioedema attacks (n = 5) were abdominal. All patients met the primary end-point; median time to unequivocal symptom relief was 0.5 (range: 0.25-2.5) h. Doses of C1 INH-nf ranged from 20.8 to 51.9 U/kg. Conclusions: Treatment of a single angioedema attack with C1 INH-nf doses of 500 U (in patients 10-25 kg), 1000 U, and 1500 U (in patients >25 kg) were well tolerated. Doses of C1 INH-nf

Original languageEnglish (US)
Pages (from-to)674-680
Number of pages7
JournalPediatric Allergy and Immunology
Volume26
Issue number7
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Complement C1 Inhibitor Protein
Hereditary Angioedemas
Angioedema
Safety
Weights and Measures

Keywords

  • Acute treatment
  • C1 esterase inhibitor
  • Children
  • Hereditary angioedema
  • Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health
  • Immunology

Cite this

Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema. / Lumry, William; Soteres, Daniel; Gower, Richard; Jacobson, Kraig W.; Li, Huamin; Chen, Hongzi; Schranz, Jennifer.

In: Pediatric Allergy and Immunology, Vol. 26, No. 7, 01.11.2015, p. 674-680.

Research output: Contribution to journalArticle

Lumry, William ; Soteres, Daniel ; Gower, Richard ; Jacobson, Kraig W. ; Li, Huamin ; Chen, Hongzi ; Schranz, Jennifer. / Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema. In: Pediatric Allergy and Immunology. 2015 ; Vol. 26, No. 7. pp. 674-680.
@article{f2b167c800d94a9695e036715d976346,
title = "Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema",
abstract = "Background: Human plasma-derived nanofiltered C1 esterase inhibitor (C1 INH-nf) is used to treat acute angioedema attacks in patients with hereditary angioedema (HAE), but data regarding use in children are sparse. Methods: Patients 2 to 25 kg). Each weight category included 2 dosing levels: C1 INH-nf (500 units [U], 1000 U) and C1 INH-nf (1000 U, 1500 U), respectively. Patients experiencing an angioedema attack were given a single intravenous dose. Primary efficacy end-point was the onset of unequivocal relief of the defining symptom within 4 h following initiation of C1 INH-nf treatment. Results: Nine children were treated: 3 (10-25 kg) received 500 U; 3 (>25 kg) received 1000 U; and 3 (>25 kg) received 1500 U. The lower weight/higher dose category (10-25 kg, 1000 U) was not successfully enrolled. All patients completed the study. Most angioedema attacks (n = 5) were abdominal. All patients met the primary end-point; median time to unequivocal symptom relief was 0.5 (range: 0.25-2.5) h. Doses of C1 INH-nf ranged from 20.8 to 51.9 U/kg. Conclusions: Treatment of a single angioedema attack with C1 INH-nf doses of 500 U (in patients 10-25 kg), 1000 U, and 1500 U (in patients >25 kg) were well tolerated. Doses of C1 INH-nf",
keywords = "Acute treatment, C1 esterase inhibitor, Children, Hereditary angioedema, Safety",
author = "William Lumry and Daniel Soteres and Richard Gower and Jacobson, {Kraig W.} and Huamin Li and Hongzi Chen and Jennifer Schranz",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/pai.12444",
language = "English (US)",
volume = "26",
pages = "674--680",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "7",

}

TY - JOUR

T1 - Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema

AU - Lumry, William

AU - Soteres, Daniel

AU - Gower, Richard

AU - Jacobson, Kraig W.

AU - Li, Huamin

AU - Chen, Hongzi

AU - Schranz, Jennifer

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: Human plasma-derived nanofiltered C1 esterase inhibitor (C1 INH-nf) is used to treat acute angioedema attacks in patients with hereditary angioedema (HAE), but data regarding use in children are sparse. Methods: Patients 2 to 25 kg). Each weight category included 2 dosing levels: C1 INH-nf (500 units [U], 1000 U) and C1 INH-nf (1000 U, 1500 U), respectively. Patients experiencing an angioedema attack were given a single intravenous dose. Primary efficacy end-point was the onset of unequivocal relief of the defining symptom within 4 h following initiation of C1 INH-nf treatment. Results: Nine children were treated: 3 (10-25 kg) received 500 U; 3 (>25 kg) received 1000 U; and 3 (>25 kg) received 1500 U. The lower weight/higher dose category (10-25 kg, 1000 U) was not successfully enrolled. All patients completed the study. Most angioedema attacks (n = 5) were abdominal. All patients met the primary end-point; median time to unequivocal symptom relief was 0.5 (range: 0.25-2.5) h. Doses of C1 INH-nf ranged from 20.8 to 51.9 U/kg. Conclusions: Treatment of a single angioedema attack with C1 INH-nf doses of 500 U (in patients 10-25 kg), 1000 U, and 1500 U (in patients >25 kg) were well tolerated. Doses of C1 INH-nf

AB - Background: Human plasma-derived nanofiltered C1 esterase inhibitor (C1 INH-nf) is used to treat acute angioedema attacks in patients with hereditary angioedema (HAE), but data regarding use in children are sparse. Methods: Patients 2 to 25 kg). Each weight category included 2 dosing levels: C1 INH-nf (500 units [U], 1000 U) and C1 INH-nf (1000 U, 1500 U), respectively. Patients experiencing an angioedema attack were given a single intravenous dose. Primary efficacy end-point was the onset of unequivocal relief of the defining symptom within 4 h following initiation of C1 INH-nf treatment. Results: Nine children were treated: 3 (10-25 kg) received 500 U; 3 (>25 kg) received 1000 U; and 3 (>25 kg) received 1500 U. The lower weight/higher dose category (10-25 kg, 1000 U) was not successfully enrolled. All patients completed the study. Most angioedema attacks (n = 5) were abdominal. All patients met the primary end-point; median time to unequivocal symptom relief was 0.5 (range: 0.25-2.5) h. Doses of C1 INH-nf ranged from 20.8 to 51.9 U/kg. Conclusions: Treatment of a single angioedema attack with C1 INH-nf doses of 500 U (in patients 10-25 kg), 1000 U, and 1500 U (in patients >25 kg) were well tolerated. Doses of C1 INH-nf

KW - Acute treatment

KW - C1 esterase inhibitor

KW - Children

KW - Hereditary angioedema

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84944161667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944161667&partnerID=8YFLogxK

U2 - 10.1111/pai.12444

DO - 10.1111/pai.12444

M3 - Article

C2 - 26171584

AN - SCOPUS:84944161667

VL - 26

SP - 674

EP - 680

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 7

ER -